Shares of Regeneron (REGN +10.1%
) roar out of the gate after the company beats
the estimate of analysts with its Q4 report and boosts its outlook
for 2012 sales on its eye drug Eylea. The news could tip off weaker sales for Roche's (RHHBY.PK
) Lucentis treatment - Regeneron's main rival in the space.